RVMD Revolution Medicines, Inc.

Nasdaq revmed.com


$ 62.00 $ -0.37 (-0.6 %)    

Friday, 07-Nov-2025 17:20:02 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 61.01
$ 60.88
$ 58.06 x 10
$ 68.00 x 18
$ 58.91 - $ 61.40
$ 29.17 - $ 63.15
2,724,421
na
11.79B
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-26-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-26-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 02-27-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-02-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-30-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-maintains-outperform-on-revolution-medicines-raises-price-target-to-80

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...

 needham-maintains-buy-on-revolution-medicines-raises-price-target-to-72

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $66 to $72.

 hc-wainwright--co-maintains-buy-on-revolution-medicines-raises-price-target-to-73

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price ta...

 stocks-rebound-eli-lilly-jumps-to-14-month-highs-whats-moving-markets-wednesday

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...

 rbc-capital-initiates-coverage-on-revolution-medicines-with-outperform-rating-announces-price-target-of-77

RBC Capital analyst Leonid Timashev initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and an...

 tango-therapeutics-touts-encouraging-data-from-early-stage-cancer-trial-raises-capital-to-fund-advancement

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with ...

 revolution-medicines-reports-42-objective-response-rate-for-elironrasib-in-heavily-pretreated-kras-g12c-nsclc-patients-co-to-highlight-data-at-aacr-nci-eortc-symposium-october-23-25-2025

Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients wit...

 mizuho-initiates-coverage-on-revolution-medicines-with-outperform-rating-announces-price-target-of-90

Mizuho analyst Joseph Catanzaro initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating and announ...

 raymond-james-maintains-strong-buy-on-revolution-medicines-raises-price-target-to-76

Raymond James analyst Sean McCutcheon maintains Revolution Medicines (NASDAQ:RVMD) with a Strong Buy and raises the price ta...

 fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

 wedbush-reiterates-outperform-on-revolution-medicines-maintains-77-price-target

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $77 price target.

 no-need-to-sell-martin-marietta-materials-cramer-says-its-just-a-great-long-term-hold

Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a pri...

Core News & Articles

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

 stifel-reinstates-buy-on-revolution-medicines-announces-85-price-target

Stifel analyst Laura Prendergast reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $85 price target.

 goldman-sachs-maintains-buy-on-revolution-medicines-raises-price-target-to-73

Goldman Sachs analyst Andrea Newkirk maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target fro...

 raymond-james-assumes-revolution-medicines-at-strong-buy-announces-price-target-of-72

Raymond James analyst Sean McCutcheon assumes Revolution Medicines (NASDAQ:RVMD) with a Strong Buy rating and announces Pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION